Dataset Information


Prognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.

ABSTRACT: Fibroblast growth factor receptor (FGFR) gene amplification has been reported in different types of cancer. We performed an up-to-date meta-analysis to further characterize the prognostic value of FGFR gene amplification in patients with cancer.A search of several databases, including MEDLINE (PubMed), EMBASE, Web of Science, and China National Knowledge Infrastructure, was conducted to identify studies examining the association between FGFR gene amplification and cancer. A total of 24 studies met the inclusion criteria, and overall incidence rates, hazard risk (HR), overall survival, disease-free survival, and 95% confidence intervals (CIs) were calculated employing fixed- or random-effects models depending on the heterogeneity of the included studies.In the meta-analysis of 24 studies, the prevalence of FGFR gene amplification was FGFR1: 0.11 (95% CI: 0.08-0.13) and FGFR2: 0.04 (95% CI: 0.02-0.06). Overall survival was significantly worse among patients with FGFR gene amplification: FGFR1 [HR 1.57 (95% CI: 1.23-1.99); p?=?0.0002] and FGFR2 [HR 2.27 (95% CI: 1.73-3.00); p<0.00001].Current evidence supports the conclusion that the outcomes of patients with FGFR gene amplified cancers is worse than for those with non-FGFR gene amplified cancers.


PROVIDER: S-EPMC4149366 | BioStudies | 2014-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5338732 | BioStudies
2020-01-01 | S-EPMC7599145 | BioStudies
1000-01-01 | S-EPMC6114946 | BioStudies
2017-01-01 | S-EPMC5167242 | BioStudies
2016-01-01 | S-EPMC5068193 | BioStudies
2020-01-01 | S-EPMC7367548 | BioStudies
2017-01-01 | S-EPMC5362463 | BioStudies
2015-01-01 | S-EPMC4344551 | BioStudies
2014-01-01 | S-EPMC4056052 | BioStudies
2016-01-01 | S-EPMC4764357 | BioStudies